{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05066997",
            "orgStudyIdInfo": {
                "id": "DX219"
            },
            "organization": {
                "fullName": "Oculis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Pivotal Study of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-1)",
            "officialTitle": "A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "pivotal-study-of-ocs-eye-drops-in-subjects-with-diabetic-macular-edema-diamond"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-10-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-02",
            "studyFirstSubmitQcDate": "2021-10-01",
            "studyFirstPostDateStruct": {
                "date": "2021-10-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Oculis",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "ICON plc",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).",
            "detailedDescription": "A Phase 2/3 Pivotal Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema\n\nStage 1: To select a dosing regimen for OCS-01 in subjects with DME, and evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 12 in subjects with DME.\n\nStage 2: To evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 52 in subjects with DME."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetic Macular Edema"
            ],
            "keywords": [
                "Topical ophthalmic suspension",
                "Eye drop"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 497,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "OCS-01",
                    "type": "EXPERIMENTAL",
                    "description": "dexamethasone ophthalmic suspension,1.5% \\[15 mg/ mL\\]",
                    "interventionNames": [
                        "Drug: Dexamethasone ophthalmic suspension (OCS-01)"
                    ]
                },
                {
                    "label": "Vehicle placebo arm",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Vehicle ophthalmic suspension",
                    "interventionNames": [
                        "Drug: Vehicle"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dexamethasone ophthalmic suspension (OCS-01)",
                    "description": "The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.\n\nStage 1: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).\n\nStage 2: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).",
                    "armGroupLabels": [
                        "OCS-01"
                    ],
                    "otherNames": [
                        "Dexamethasone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vehicle",
                    "description": "The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.\n\nStage 1: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).\n\nStage 2: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).",
                    "armGroupLabels": [
                        "Vehicle placebo arm"
                    ],
                    "otherNames": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change in BCVA (Best Corrected Visual Acuity)",
                    "description": "Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the EDTRS chart representing better visual acuity",
                    "timeFrame": "Stage 1: Week 6; Stage 2: Week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria (selection) - Stage 1:\n\n1. Have a signed informed consent form before any study-specific procedures are performed.\n2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of \u2265310 \u00b5m by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).\n3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus at Visit 1 (Screening).\n\nInclusion Criteria (selection) - Stage 2:\n\n1. Have a signed informed consent form before any study-specific procedures are performed.\n2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of \u2265310 \u00b5m by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).\n3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus prior to Visit 1 (Screening).\n\nExclusion criteria (selection) - Stage 1 and Stage 2:\n\n1. Have macular edema considered to be because of a cause other than DME.\n2. Have a decrease in BCVA because of causes other than DME.\n3. Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Oculis Study Leader",
                    "role": "CONTACT",
                    "phone": "+41 21 711 3970",
                    "email": "info@oculis.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "David S. Boyer, MD",
                    "affiliation": "Retina-Vitreous Associates Medical Group",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Oculis Investigative Site - Retina Vitreous Associates Medical Group",
                    "status": "RECRUITING",
                    "city": "Beverly Hills",
                    "state": "California",
                    "zip": "90211",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.07362,
                        "lon": -118.40036
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008269",
                    "term": "Macular Edema"
                },
                {
                    "id": "D000004487",
                    "term": "Edema"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008268",
                    "term": "Macular Degeneration"
                },
                {
                    "id": "D000012162",
                    "term": "Retinal Degeneration"
                },
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7657",
                    "name": "Edema",
                    "asFound": "Edema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11261",
                    "name": "Macular Edema",
                    "asFound": "Macular Edema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11260",
                    "name": "Macular Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14997",
                    "name": "Retinal Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "C000018038",
                    "term": "Dexamethasone acetate"
                },
                {
                    "id": "C000101468",
                    "term": "BB 1101"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M199152",
                    "name": "BB 1101",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}